Clinical Trial Update: Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE [Phase 3]

View source ↗

Summary

A long-term, open-label Phase 3 trial evaluating an oral extended-release deucrictibant tablet for prophylaxis of angioedema attacks in adolescents and adults w…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hereditary Angioedema

Drugs mentioned

• Deucrictibant extended-release tablet (deucrictibant)

Snippet

Sponsor: Pharvaris Netherlands B.V. | Conditions: Hereditary Angioedema (HAE) | Phase 3 | Status: RECRUITING